A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

Archives of Internal Medicine

Volumn 164, Issue 19, 2004, Pages 2097-2104

  Chiquette, Elaine ^a,b   Ramirez, Gilbert ^d   DeFronzo, Ralph ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SANOFI   (France)

^c BRISTOL MYERS SQUIBB   (United States)

^d DES MOINES UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 7044253431     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.19.2097     Document Type: Review

References (61)

1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
2. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care. 1998;21:1138-1145.
3. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovasculardisease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-976.
4. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322:882-889.
5. Dorn JM, Schisterman EF, Winkelstein W, Trevisan M. Body mass index and mortality in a general population sample of men and women: the Buffalo Health Study. Am J Epidemiol. 1997;146:919-931.
6. Bender R, Trautner C, Spraul M, Berger M. Assessment of excess mortality in obesity. Am J Epidemiol. 1998;147:42-48.
7. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonyl ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPOS 33). Lancet. 1998;352:837-853.
9. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 individuals with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
10. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
11. Lord J, Paisley S, Taylor R. The Clinical Effectiveness and Cost-effectiveness of Rosiglitazone for Type 2 Diabetes Mellitus. London, England; National Institute for Clinical Excellence; August 2000.
12. Chilcott J, Wight J, Jones ML, Tappenden P. The Clinical Effectiveness and Cost-effectiveness of Pioglitazone for Type 2 Diabetes Mellitus. London, England: National Institute for Clinical Excellence; March 2001.
13. Bradburn MJ, Deeks JJ, Altman DG, Newton HJ. sg104: Metan: an alternative meta-analysis command. In: Newton HJ, ed. The Stata Technical Bulletin Reprints, Volume 8. College Station, Tex: Stata Corp; 1999:86-100.
14. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL; The Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care. 2000;23:1605-1611.
15. Kaneko T, Baba S, Toyota T. Dose finding study of AO-4833 in patients with non-insulin dependent diabetes mellitus (NIDDM) on diet therapy alone: double-blind comparative study on four dosages. Jap J Clin Exp Med. 1997;74:1250-1277.
16. Kaneko T, Baba S, Toyota T. Clinical evaluation of an insulin-resistance improving agent, AD-4833, in patients with non-insulin dependent diabetes mellitus (NIDDM) on diet therapy alone: a placebo controlled double blind clinical study. Jap J Clin Exp Med. 1997;74:1491-1514.
17. Kaneko T, Baba S, Toyota T. Dose finding study of AD-4833 in patients with non-insulin dependent diabetes mellitus (NIDDM) on treatment with a sulfonylurea drug: single blind comparative study on four dosages. Jap J Clin Exp Med. 1997;74:1278-1306.
18. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL; The Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22:1395-1409.
19. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251-257.
20. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10-17.
21. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther. 2003;25:1074-1095.
22. Rosenblatt S, Miskin B. Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12:413-423.
23. Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res. 2002;34:589-595.
24. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. Arandomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226-1232.
25. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; The Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280-288.
26. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A; The Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemie control in patients with type 2 diabetes. Diabetes Care. 2001;24:308-315.
27. Barnett AH, Grant PJ, Hitman GA, et al; Indo-Asian Trial Investigators. Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabet Med. 2003;20:387-393.
28. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Ones Metab. 1999;1:165-172.
29. Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulfonylurea [abstract]. Diabetes. 2001;50:A135.
30. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002;18:127-134.
31. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000;17:40-47.
32. Vongthavaravat V, Wajchenberg BL, Waitman JN, et al; 125 Study Group. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin. 2002;18:456-461.
33. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702.
34. Moran EG, Salzman A, Yan Y, Patwardhan R. Rosiglitazone. BRL 49653: A 26-week randomized, double-blind, double-dummy, multicentered study to evaluate the efficacy, safety and tolerability of rosiglitazone when administered to patients with non-insulin dependent diabetes mellitus (NIDDM) who are inadequately controlled on a maximal dose (20-mg/day) of glyburide: report 079 phase IIIA: final clinical report. Excerpt in: Lord J, Paisley S, Taylor R. The Clinical Effectiveness and Cost-Effectiveness of Rosiglitazone for Type 2 Diabetes Mellitus. London, England: National Institute for Clinical Excellence; August 2000.
35. Lowry FS, Bevivino MV, Salzman A, Yan Y, Patwardhan R. Rosiglitazone: BRL 49653: a 26-week randomized, double-blind, double-dummy, multicenter study to evaluate the efficacy, safety and tolerability of rosiglitazone 4 mg bd when administered to patients with non-insulin dependent diabetes mellitus (NIDDM) who are inadequately controlled on a maintenance dose (2.5g/day) of metformin: report 093 phase IIIA: final clinical report. Excerpt in: Lord J, Paisley S, Taylor R. The Clinical Effectiveness and Cost-Effectiveness of Rosiglitazone for Type 2 Diabetes Mellitus. London, England: National Institute for Clinical Excellence; August 2000.
36. Hutchman J, Salzman A, Biswas N, Patwardhan R. Rosiglitazone: BRL 49653: a 26-week randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy, safety and tolerability of rosiglitazone when administered once daily to patients with non-insulin dependent diabetes mellitus (NIDDM) who are inadequately controlled on at least half-maximal dose (10 mg/day) of glyburide: report 096 phase IIIA: final clinical report. Excerpt in: Lord J, Paisley S, Taylor R. The Clinical Effectiveness and Cost-Effectiveness of Rosiglitazone for Type 2 Diabetes Mellitus. London, England: National Institute for Clinical Excellence; August 2000.
37. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
38. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
39. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136:575-581.
40. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979;2:120-126.
41. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
42. Zavaroni I, Bonini L, Gasparini P, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism. 1999;48:989-994.
43. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
44. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES 111 participants age 50 years and older. Diabetes. 2003;52:1210-1214.
45. Wurch T, Junquero D, Delhon A, Pauwels J. Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:133-140.
46. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-2791.
47. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients. Diabetologia. 2001;44:2210-2219.
48. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710-719.
49. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23:1792-1823.
50. Scherbaum W, Burkhard G, the German pioglitazone study group. Pioglitazone reduces blood pressure in patients with type 2 diabetes [abstract]. Diabetes. 2001;50(suppl 2):A462.
51. Bakris GL, Dole JF, Porter LE, Huang C, Freed M. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus [abstract] Diabetes. 2000;49(suppl 1):A96.
52. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463-478.
53. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
54. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol. 2003;92:34J-41J.
55. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493-2499.
56. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:1529-1535.
57. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.
58. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003;146:E5.
59. Takagi T, Yamamuro A, Tamita K, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol. 2002;89:318-322.
60. Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J. 2004;147:e23.
61. Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25:1737-1743.